Loading... Please wait...
Sort by:

therapy-trends-jpg.jpg
Therapy Trends
reports deliver critical and unbiased intelligence derived from in-depth interviews with the world’s foremost thought leaders on the current and future treatment landscapes in major disease areas. Research is focused on the major battlegrounds for market share and answers critical business questions about potential product positioning and competitiveness. Through continuous monitoring and frequent re-engagement with stakeholders, the FirstWord Therapy Trends analyst team delivers quarterly updates with each report ensuring insights remain current and relevant.

  • Targeted Therapies in Asthma: KOL Insight  2020
    Learn More Targeted Therapies in Asthma: KOL Insight 2020
    Targeted Therapies in Asthma: KOL Insight Expectations that AstraZeneca's Fasenra would be a more potent anti-IL5 antagonist than GSK's Nucala or Teva's Cinqair have not been realised – why? What...
  • KOL Insight: Melanoma [2020]
    Learn More KOL Insight: Melanoma [2020]
    Therapy Trends KOL Insight: Melanoma [2020] Why do KOLs foresee an expansion of Merck's anti-PD-1 therapy Keytruda in the adjuvant setting? Could Eli Lilly/Innovent Biologics' sintilimab/ipilimumab...
  • KOL Insight: Non-Small Cell Lung Cancer [2020]
    Learn More KOL Insight: Non-Small Cell Lung Cancer [2020]
    Therapy Trends KOL Insight: Non-Small Cell Lung Cancer [2020] How do KOLs believe the integration of PD-1/L1 inhibitors into attempts to cure NSCLC could shift the treatment paradigm? What underpins...
  • KOL Insight: Spinal Muscular Atrophy  [2020]
    Learn More KOL Insight: Spinal Muscular Atrophy [2020]
    Therapy Trends KOL Insight: Spinal Muscular Atrophy [2020] Despite its price, KOLs see Novartis' Zolgensma as a 'game changer' in infant SMA but will safety concerns around the intrathecal formulation...
  • KOL Insight: Renal Cell Carcinoma  [2020]
    Learn More KOL Insight: Renal Cell Carcinoma [2020]
    Therapy Trends KOL Insight: Renal Cell Carcinoma [2020] Combination immunotherapies have revolutionised the treatment of advanced RCC but how do KOLs assess the clinical value of Merck & Co./Pfizer's...
  • KOL Insight: Colorectal Cancer  [2020]
    Learn More KOL Insight: Colorectal Cancer [2020]
    Therapy Trends KOL Insight: Colorectal Cancer [2020] KOLs describe the approval of Array Biopharma/Ono/Pierre Fabre's Braftovi in combination with cetuximab for the second-line treatment of patients with...
  • KOL Insight: Ulcerative Colitis [2020]
    Learn More KOL Insight: Ulcerative Colitis [2020]
    Therapy Trends KOL Insight: Ulcerative Colitis [2020] KOLs are enthusiastic about Johnson & Johnson's recently launched Stelara (ustekinumab) for its favourable safety profile and patient-friendly...
  • KOL Insight: Psoriasis [2020]
    Learn More KOL Insight: Psoriasis [2020]
    Therapy Trends KOL Insight: Psoriasis [2020] Anti-TNF's grip on the psoriasis market will come under pressure due to biosimilar competition and the arrival of new anti-IL17 and anti-IL23 therapies. What...
  • KOL Insight: Type 2 Diabetes Mellitus [2020]
    Learn More KOL Insight: Type 2 Diabetes Mellitus [2020]
    Therapy Trends KOL Insight: Type 2 Diabetes Mellitus What are the prospects for emerging GLP-1 receptor agonists such as Eli Lilly's tirzepatide and Sanofi's efpeglenatide and how can they differentiate...
  • KOL Insight: Bladder Cancer [2020]
    Learn More KOL Insight: Bladder Cancer [2020]
    Therapy Trends KOL Insight: Bladder Cancer KOLs expect Pfizer/Merck Group's Bavencio to be practice changing in the first-line maintenance treatment of locally advanced or metastatic urothelial cancer...
  • KOL Insight: Atopic Dermatitis  [2020]
    Learn More KOL Insight: Atopic Dermatitis [2020]
    Therapy Trends KOL Insight: Atopic Dermatitis What advantages do KOLs see for Eli Lilly & Co/Almirall's pipeline lebrikizumab and what are its competitive prospects against AstraZeneca/Leo Pharma's...
  • KOL Insight: Ovarian Cancer [2020]
    Learn More KOL Insight: Ovarian Cancer [2020]
    Therapy Trends KOL Insight: Ovarian Cancer PARP inhibitors are set to further disrupt frontline treatment but what factors will govern the decision between Lynparza and Zejula? Despite PIII trial...
  • KOL Insight: Hepatocellular Carcinoma [2020]
    Learn More KOL Insight: Hepatocellular Carcinoma [2020]
    Therapy Trends KOL Insight: Hepatocellular Carcinoma KOLs anticipate Tecentriq and Avastin combination will become the standard of care for Hepatocellular Carcinoma (HCC) though COVID-19 may hinder the...
  • Multiple Myeloma: KOL Insight 2020
    Learn More Multiple Myeloma: KOL Insight 2020
    Multiple Myeloma: KOL Insight Darzalex has been one of the leading success stories in recent years, but will it become a standard-of-care first line therapy for all newly diagnosed patients? KOLs expect...
  • Duchenne Muscular Dystrophy (DMD): KOL Insight  2020
    Learn More Duchenne Muscular Dystrophy (DMD): KOL Insight 2020
    Targeted Therapies in DMD: KOL Insight Are the days of steroids being the standard of care for DMD coming to an end? What benefits do KOLs identify for new oral agents such as Catabasis Pharmaceuticals'...
  • KOL Insight: Epilepsy [2020]
    Learn More KOL Insight: Epilepsy [2020]
    Therapy Trends KOL Insight: Epilepsy Why, despite regulatory setbacks, do KOLs consider Zogenix's Fintepla to be highly promising for Dravet syndrome? How do KOLs think safety concerns could be addressed...

customer.service@firstwordpharma.com

All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved